Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR versus placebo for exudative age-related macular degeneration
NL-OMON25954Active, not recruiting
- Start
- Feb 2000
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial in age-related macular degeneration (AMD) comparing Sandostatin LAR with Placebo (2 arms). Primary endpoints: Visual acuity, Contrast sensitivity and 2 more. Started Feb 2000; status: active, not recruiting.
02
Drugs
octreotide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON25954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25954.